EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score

Yaming Zhang, Min Zhang, Yali Huang, Junzhao Wan, Ping Liu, Ping Wang, Zhen Zhou, Fangya Hu, Jianta Wang, Dan Ma, Qian Kang

Frontiers in Oncology · 19.05.2026 · 16

DOI: 10.3389/fonc.2026.1780304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.05.2026. Verfasst von Yaming Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Key Laboratory of Hematological Malignancies at Affiliated Hospital of Guizhou Medical University, Guiyang, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

ASXL1 is a frequently mutated gene in acute myeloid leukemia (AML) and is clinically recognized as an adverse prognostic marker, yet its clinical impact remains markedly heterogeneous.

Methods

Utilizing the BeatAML cohort, we integrated genomic, transcriptomic, immunophenotypic, and drug-sensitivity data to delineate this variability.

Results

Although ASXL1 mutations remained an independent adverse factor in multivariable analyses, survival outcomes did not differ significantly between ASXL1 -mutated patients and those lacking other high-risk lesions after excluding co-occurring adverse mutations, suggesting that ASXL1 status alone does not uniformly dictate prognosis. By stratifying ASXL1 -mutated patients based on treatment response, we identified two biologically distinct subsets-complete remission (CR) versus relapsed/refractory (R/R)-characterized by divergent clinical outcomes. Comparative analyses revealed distinct transcriptional profiles, including upregulated MAP3K15 expression in ASXL1 -mutated cases, alongside consistent immunophenotypic downregulation of CD11b, CD123, and HLA-DR in R/R patients. Leveraging these routinely measured markers, we developed a three-parameter ImmuScore that robustly stratified prognosis in both the BeatAML cohort and an independent clinical validation set. Importantly, the ImmuScore captured functional drug-response patterns: patients with low scores displayed significantly higher Z-scores-indicating reduced sensitivity across multiple chemotherapeutic and targeted agents.

Discussion

These findings link immunophenotypic signatures to therapeutic vulnerability, providing a mechanistic explanation for treatment failure in a subset of ASXL1 -mutated AML. To address potential small-sample bias, Firth penalized regression was applied. Collectively, this study demonstrates that ASXL1 -mutated AML is not a monolithic high-risk entity. The ImmuScore provides a biologically informed and clinically feasible tool to identify truly high-risk ASXL1 -mutated patients, potentially guiding personalized therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

ASXL1acute myeloid leukemia (AML)immuScoremutationrisk

Autor:innen und Institutionen

  • Department of Hematology, Key Laboratory of Hematological Malignancies at Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Me…
  • Department of Pharmacy, The Fourth People's Hospital of Guiyang, Guiyang, China.
  • Natural Products Research Center of Guizhou Province, Guiyang, China.

Zitieren

APA

Zhang, Y., Zhang, M., Huang, Y., Wan, J., Liu, P., Wang, P., Zhou, Z., Hu, F., Wang, J., Ma, D., & Kang, Q. (2026). Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1780304

Vancouver

Zhang Y, Zhang M, Huang Y, Wan J, Liu P, Wang P, et al. Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1780304

BibTeX
@article{Zhang2026,
  author = {Zhang, Yaming and Zhang, Min and Huang, Yali and Wan, Junzhao and Liu, Ping and Wang, Ping and Zhou, Zhen and Hu, Fangya and Wang, Jianta and Ma, Dan and Kang, Qian},
  title = {Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1780304}
}
Kostenlos starten →